These innovative agents represent a significant advancement in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose https://roxannyrxh395360.blogacep.com/44634068/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide